上海复旦复华科技股份有限公司 对会计师事务所 2024 年度审计履职情况的评估报告 职业风险基金上年度（2024 年末）数：6,485.12 万元； 永拓会计师事务所不存在违反《中国注册会计师职业道德守则》对独立性要 求的情形。 组织形式：特殊普通合伙企业 注册地址：北京市朝阳区关东店北街 1 号 2 幢 13 层 首席合伙人：吕江 永拓会计师事务所具有良好的投资者保护能力，能承担因审计失败导致的民 事赔偿责任，职业风险基金计提、质押保险购买符合相关规定。近三年，永拓会 计师事务所不存在在职业行为相关民事诉讼中承担民事责任的情况。 上海复旦复华科技股份有限公司（以下简称"公司"）聘请永拓会计师事务 所（特殊普通合伙）（以下简称"永拓"）作为公司2024年度审计机构。根据《中 华人民共和国公司法》《中华人民共和国证券法》《国有企业、上市公司选聘会 计师事务所管理办法》和《上海证券交易所上市公司自律监管指引第1号——规 范运作》等相关规范性文件的规定，公司对永拓2024年度履职情况进行了评估， 具体情况汇报如下： 一、2024年年审会计师事务所基本情况 机构名称：永拓会计师事务所（特殊普通合伙） 成立日期：201 ...

上海复旦复华科技股份有限公司董事会 2025 年 4 月 28 日 上海复旦复华科技股份有限公司第十一届董事会 关于前期会计差错更正及追溯调整的说明 （以下无正文） 上海复旦复华科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日 召开第十一届董事会第十一次会议，会议审议通过了《关于前期会计差错更正及 追溯调整的议案》，根据相关规定，公司第十一届董事会就本次前期会计差错更 正及追溯调整事项说明如下： 本次前期会计差错更正及追溯调整符合《企业会计准则第 28 号——会计政 策、会计估计变更和差错更正》、中国证券监督管理委员会《公开发行证券的公 司信息披露编报规则第 19 号——财务信息的更正及相关披露》等相关文件的规 定，更正后的财务数据及财务报表能够更真实、全面、客观地反映公司的财务状 况和经营成果，不存在损害公司和全体股东利益的情形，同意本次前期会计差错 更正及追溯调整事项。 董事长:宋 正 董 事:李 燕 董 事:陆 熊 ww 董 事:张静媛 独立董事:任永康 独立董事:倪 薇 独立董事:赵向雷 （本页无正文，系《上海复旦复华科技股份有限公司第十一届董事会关于前期 会计差错更正及追溯调整 ...

Financial Performance - The net profit attributable to shareholders for 2024 is a loss of RMB -133,209,876.48, with retained earnings at RMB -210,842,769.27 as of December 31, 2024[3]. - The basic earnings per share for 2024 is -0.195, a significant decrease from -0.032 in 2023[18]. - The operating revenue for 2024 is RMB 645,322,768.13, down 5.05% from RMB 679,678,938.29 in 2023[20]. - The net cash flow from operating activities for 2024 is RMB -14,439,859.13, a decline of 305.29% compared to RMB 7,033,862.40 in 2023[20]. - The total assets decreased by 19.52% to RMB 1,424,140,492.46 in 2024 from RMB 1,769,467,818.60 in 2023[20]. - The weighted average return on equity for 2024 is -18.84%, compared to -2.77% in 2023[18]. - The company plans no profit distribution or capital reserve transfer due to the loss in 2024[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is RMB -136,972,864.12, compared to RMB -50,129,141.81 in 2023[20]. - The company reported a significant impairment provision for inventory by its subsidiary, which contributed to the loss[19]. - The company’s net assets attributable to shareholders decreased by 17.96% to RMB 637,446,077.87 as of the end of 2024[20]. Revenue Breakdown - In 2024, the company's operating revenue was CNY 645.32 million, a decrease of 5.05% compared to the previous year[30]. - The pharmaceutical segment generated revenue of CNY 302.37 million, down 11.71% year-on-year, accounting for 46.86% of total revenue[30]. - The net profit from the pharmaceutical segment was CNY -20.53 million, a decrease of CNY 20.54 million compared to the previous year[30]. - Shanghai Zhonghe Software's revenue for 2024 reached CNY 276.70 million, a year-on-year increase of 2.21%, accounting for 42.88% of the company's total revenue; net profit attributable to shareholders decreased by 2.52% to CNY 5.59 million[33]. - The park segment's total revenue for 2024 was CNY 41.88 million, a year-on-year increase of 4.38%, but net profit attributable to shareholders was -CNY 107.27 million, a decrease of CNY 108.41 million compared to the previous year[35]. Market Challenges - The company faced significant challenges due to policy changes in the pharmaceutical industry, including the normalization of centralized procurement and adjustments to the medical insurance drug list[31]. - The average price reduction for the tenth batch of national organized drug procurement reached approximately 70%, with the highest reduction at 96%[96]. - The national drug procurement policy has been institutionalized, focusing on reducing drug prices while ensuring supply and quality[105]. - The pharmaceutical sector faces risks from policy changes, price reductions, and rising production costs, necessitating strategic adjustments[164]. Research and Development - The company has initiated two new product projects and is increasing R&D investment to enhance product development[31]. - The company is focusing on specialized drugs in areas such as digestive, neurological, anti-tumor, and circulatory system treatments[48]. - The company is committed to improving its quality management system in compliance with the Drug Administration Law[31]. - The company’s R&D investment amounted to 2,666.49 million RMB, representing 6.84% of its operating revenue and 5.52% of its net assets[124]. - The company has increased its R&D focus on generic drug quality and efficacy consistency evaluations, particularly in the field of neurological medications[124]. Strategic Initiatives - The company is focusing on expanding its market presence in pharmaceuticals, software, and park operations while enhancing core business capabilities[30]. - The company is actively researching and planning the layout and expansion of park business in Fengxian, integrating its pharmaceutical and software operations[36]. - The company is exploring strategic collaborations and acquisitions to support its growth and market expansion initiatives[108]. - The company plans to enhance its technological capabilities and expand its market presence in the industrial internet sector[56]. Governance and Compliance - The company maintains independence from its controlling shareholder, ensuring no interference in operational decisions[173]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate reporting to all shareholders[175]. - The company has established a robust internal control system to enhance management and risk prevention capabilities[174]. - The board of directors consists of nine members, including three independent directors, meeting legal requirements and ensuring effective governance through various committees[172]. Employee and Management - The company employs a total of 1,414 staff members, with 60 in the parent company and 1,354 in major subsidiaries[197]. - The technical personnel comprised 936 employees, representing approximately 66% of the total workforce[197]. - The company has implemented a compensation policy linking employee income to individual performance and company growth[198]. - The remuneration for senior management is linked to the company's performance evaluation[188]. Future Outlook - The company projects a total revenue of 720 million yuan and operating costs of 430 million yuan for 2025, with expenses estimated at 290 million yuan[158]. - The company aims to strengthen its financial performance and operational efficiency in the next fiscal year[182]. - The company is committed to increasing R&D investment and enhancing production efficiency to maintain competitiveness in the pharmaceutical market[160]. - The company is actively involved in research and development of new technologies to drive future growth[182].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 160,921,239.79, representing a 3.50% increase compared to CNY 155,481,059.50 in the same period last year[4] - The net profit attributable to shareholders of the listed company was a loss of CNY 8,124,350.92, an improvement from a loss of CNY 11,103,708.12 in the previous year[4] - The net cash flow from operating activities was a negative CNY 12,297,098.90, significantly improved from a negative CNY 44,759,734.75 in the same period last year[4] - Total operating revenue for Q1 2025 was CNY 160,921,239.79, an increase of 3.5% compared to CNY 155,481,059.50 in Q1 2024[20] - Net profit for Q1 2025 was a loss of CNY 8,241,795.37, an improvement from a loss of CNY 11,140,434.51 in Q1 2024[21] - The net cash flow from operating activities for Q1 2025 was a negative CNY 12,297,098.90, compared to a negative CNY 44,759,734.75 in Q1 2024, indicating a significant reduction in cash outflow[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,475,883,220.15, reflecting a 3.63% increase from CNY 1,424,140,492.46 at the end of the previous year[5] - Total current assets amounted to ¥790,428,780.05, up from ¥732,584,482.39, reflecting a growth of 7.9%[15] - The company's total assets reached ¥1,475,883,220.15, compared to ¥1,424,140,492.46, indicating an increase of 3.6%[15] - Short-term borrowings increased to ¥400,250,000.00 from ¥314,620,000.00, representing a rise of 27.2%[16] - Total liabilities rose to ¥804,607,165.99, up from ¥746,572,294.72, marking an increase of 7.8%[16] - The company's equity decreased slightly to ¥679,346,942.00 from ¥684,712,010.00, a decline of 0.5%[16] Shareholder Information - The equity attributable to shareholders of the listed company decreased by 0.97% to CNY 631,271,378.74 from CNY 637,446,077.87 at the end of the previous year[5] - Basic and diluted earnings per share were both CNY -0.0120, an improvement from CNY -0.0162 in the same period last year[5] - The total number of ordinary shareholders at the end of the reporting period was 78,478[10] Cash Flow and Financing - Cash inflow from financing activities in Q1 2025 totaled CNY 217,880,000.00, compared to CNY 108,146,444.33 in Q1 2024, showing a substantial increase of 101.5%[25] - The company reported cash and cash equivalents of ¥156,919,426.12 as of March 31, 2025, an increase of 68.9% from ¥92,749,298.70 on December 31, 2024[14] - Net cash flow from financing activities was $77.93 million, a significant improvement compared to a net outflow of $23.22 million in the previous period[26] - The total cash and cash equivalents at the end of the period increased to $156.61 million, up from $233.66 million at the end of the previous period[26] - Cash outflows from financing activities totaled $139.95 million, slightly higher than $131.36 million in the previous period[26] Government Subsidies and R&D - The company recognized government subsidies amounting to CNY 3,649,213.62, which positively impacted the financial results[6] - Research and development expenses for Q1 2025 were CNY 6,453,958.83, down from CNY 8,191,675.26 in Q1 2024, reflecting a decrease of 21.2%[21] Market and Product Development - The company has no significant new product launches or technological developments reported in the current period[13] - There are no updates on market expansion or mergers and acquisitions in the latest financial report[13] Other Comprehensive Income - Other comprehensive income for Q1 2025 was CNY 1,949,651.79, compared to a loss of CNY -3,537,062.67 in Q1 2024, indicating a positive turnaround[22]

特此公告。 上海复旦复华科技股份有限公司董事会 根据上海证券交易所发布的上市公司分行业信息披露指引《上海证券交易所 上市公司自律监管指引第 3 号——行业信息披露》及《关于做好主板上市公司 2025 年第一季度报告披露工作的重要提醒》相关要求，上海复旦复华科技股份 有限公司下属子公司上海复旦复华药业有限公司 2025 年第一季度主要经营数据 披露如下： 1 主营业务分行业情况 分行业 营业收入 营业成本 毛利率 （%） 营业收入 比上年增 减（%） 营业成本 比上年增 减（%） 毛利率比 上年增减 （%） 药业 72,949,010.38 34,689,081.66 52.45 -5.26 8.18 -5.91 主营业务分产品情况 分产品 营业收入 营业成本 毛利率 （%） 营业收入 比上年增 减（%） 营业成本 比上年增 减（%） 毛利率比 上年增减 （%） 消化系统 药品 33,411,578.68 11,267,124.50 66.28 5.35 13.60 -2.45 神经系统 用药品 19,561,885.06 13,793,474.82 29.49 -17.76 -2.17 -11.23 抗肿瘤药 ...

公司代码：600624 公司简称：复旦复华 上海复旦复华科技股份有限公司 2024年度内部控制评价报告 上海复旦复华科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变 ...

证券代码：600624 证券简称：复旦复华 公告编号：临2025-021 上海复旦复华科技股份有限公司 关于计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海复旦复华科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日 召开第十一届董事会第十一次会议，会议审议通过了《关于计提资产减值准备的 议案》（同意 7 票，弃权 0 票，反对 0 票），本次计提资产减值准备需提交股东大 会审议。现将本次计提资产减值准备的具体情况公告如下： 一、计提资产减值准备情况概述 为真实反映上海复旦复华科技股份有限公司（以下简称"公司"）2024 年度 资产和财务状况，根据《企业会计准则》及公司会计政策的相关规定，公司对截 至 2024 年 12 月 31 日的各项资产进行了全面清查，通过分析、评估，基于谨慎 性原则，对存在减值迹象的相关资产进行了减值测试并计提相应的减值准备。公 司 2024 年度计提各项资产减值准备合计 83,180,008.27 元。明细如下： | 项 目 | 资产名称 | 金 额（元 ...

上海复旦复华科技股份有限公司 董事会审计委员会2024年度履职报告 倪薇，女，1968年7月出生，汉族，中共党员，本科学历，中国注册会计师， 税务师，大学讲师。曾就职于上海旅游高等专科学校、上海金城会计师事务所有 限公司、上海事诚会计师事务所有限公司，历任教师、审计员、合伙人等职务。 现任上海新沃会计师事务所有限公司主任会计师、党支部书记，上海复旦复华科 技股份有限公司独立董事。 任永康，男，1968年8月出生，汉族，学士学位。曾就职于中国外轮理货公 司、上海港务局、上海交运局、上海外高桥保税区，历任理货员、业务员、营业 部经理、浦西部经理等职务。现任上海航天技术研究院调研员、上海复旦复华科 技股份有限公司独立董事。 赵向雷，男，1963 年 3 月出生，汉族，中共党员，硕士研究生学历，高级 经济师。曾就职于中国人民银行总行金融管理司、中国银行西安市分行、中国银 行港澳管理处、中银国际控股、中银国际控股北京代表处，历任副主任科员、科 长、副处长、经理、执行董事等职务。2002 年 2 月加入中银国际证券股份有限 公司，历任公司资金部、风险管理部、人力资源部主管，风险总监兼合规总监， 1 业务总监等职务。现任上 ...

上海复旦复华科技股份有限公司 董事会审计委员会对会计师事务所 2024 年度履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《国有企业、上 市公司选聘会计师事务所管理办法》《上海证券交易所上市公司自律监管指引第 1号——规范运作》和《公司章程》等规定和要求，董事会审计委员会本着勤勉 尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对会计师事务所2024 年度履行监督职责的情况汇报如下： 一、年审会计师事务所基本情况 1.会计师事务所基本情况 机构名称：永拓会计师事务所（特殊普通合伙） 成立日期：2013 年 12 月 20 日 组织形式：特殊普通合伙企业 注册地址：北京市朝阳区关东店北街 1 号 2 幢 13 层 首席合伙人：吕江 董事会审计委员会第四次会议审议通过了《关于续聘会计师事务所的议案》， 并将该议案提交公司第十一届董事会第三次会议审议。公司于2024年4月28日召 开的第十一届董事会第三次会议及2024年6月5日召开的2023年年度股东大会审 议通过了《公司关于续聘会计师事务所的议案》，同意公司续聘永拓会计师事务 所（特殊普通合伙）作为公司2024年度财务审计机构和内 ...

本次前期会计差错更正及追溯调整符合财政部、证监会、上海证券交易所等 有关规定，更正后的财务数据及财务报表有利于更客观、公允地反映公司的财务 状况和经营成果，决策程序符合有关法律、法规和《公司章程》的规定，不存在 损害公司及全体股东利益的情形，同意本次会计差错更正及追溯调整事项。 （以下无正文） 1 （本页无正文，为《上海复旦复华科技股份有限公司第十一届监事会关于前期 会计差错更正及追溯调整的说明》签字页 ) 上海复旦复华科技股份有限公司第十一届监事会 关于前期会计差错更正及追溯调整的说明 上海复旦复华科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日 召开第十一届监事会第十次会议，会议审议通过了《关于前期会计差错更正及追 溯调整的议案》，根据相关规定，公司第十一届监事会就本次前期会计差错更正 及追溯调整事项说明如下： 上海复旦复华科技股份有限公司监事会 2025 年 4 月 28 日 ( 本页无正文, 为《上海复旦复华科技股份有限公司第十一届监事会关于前期 会计差错更正及追溯调整的说明》签字页 ) 监事会主席:翁磊钢 事:沈忠伟 监 徐 微 蒋鑫伟 羌海燕 丁茜茜 for At 2 （本页 ...